Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

71.76 -1.58 (-2.15%)
Streaming Delayed Price Updated: 1:33 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
News headline image
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
NASDAQ:HALO, a strong growth stock, setting up for a breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Halozyme Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Preview: Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 20, 2024 ↗
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:HALO. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease ↗
Michael Shpigelmacher, Founder and CEO of Bionaut Labs, with the company’s micro-robot designed to swim through the central nervous system into the brain to treat disease now on trial in the U.S. 
Via Benzinga
News headline image
NASDAQ:HALO, an undervalued stock with good fundamentals. ↗
Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued. 
Via Chartmill
News headline image
NASDAQ:HALO, a strong growth stock, setting up for a breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients ↗
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo. 
Via Benzinga
News headline image
NASDAQ:HALO: good value for what you're paying. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗
In the world of growth stocks, NASDAQ:HALO shines as a value proposition. 
Via Chartmill
News headline image
3 Biotech Stocks to Sell in January Before They Crash and Burn ↗
The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell. 
Via InvestorPlace
News headline image
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion ↗
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights. 
Via Benzinga
News headline image
Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe ↗
Roche's Tecentriq SC, the EU's first subcutaneous PD-(L)1 immunotherapy, approved for faster, 7-minute injections 
Via Benzinga
News headline image
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond ↗
Healthcare stocks have underperformed in 2023, but that is expected to change this year. 
Via The Motley Fool
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
Investors should take note of NASDAQ:HALO, a growth stock that remains attractively priced. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗
Investors should take note of NASDAQ:HALO, a growth stock that remains attractively priced. 
Via Chartmill
News headline image
For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals. ↗
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
NASDAQ:HALO is showing good growth, while it is not too expensive. ↗
Despite its growth, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains within the realm of affordability. 
Via Chartmill
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.